Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490514 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2TDP1KDM4EALDH1A1ALOX15 | |
| SCHEMBL6140631 | 0.80 | S1PR2 (0.36) | HSP90AB1ALDH1A1ALOX15TSHRPOLB | |
| SCHEMBL14618155 | 0.80 | HSP90AB1 (0.33) | HSP90AB1ALDH1A1ALOX15TSHR | |
| SCHEMBL18068190 | 0.80 | HSP90AB1 (0.37) | HSP90AB1KDM4EALDH1A1ALOX15TSHR | |
| SCHEMBL1762646 | 0.80 | NOS3 (0.39) | SMN1; SMN2HSP90AB1KDM4EALDH1A1ALOX15 | |
| SCHEMBL22312575 | 0.78 | SMN1; SMN2 (0.34) | SMN1; SMN2TDP1KDM4EALDH1A1ALOX15 | |
| SCHEMBL10854619 | 0.78 | SMN1; SMN2 (0.34) | SMN1; SMN2TDP1KDM4EALDH1A1ALOX15 | |
| SCHEMBL5672114 | 0.77 | NOS3 (0.42) | KDM4EALDH1A1POLBHPGDKMT2A | |
| SCHEMBL218052 | 0.76 | — | — | |
| Ammonia Solution, Strong SCHEMBL27915759 | 0.76 | ALDH1A1 (0.50) | SMN1; SMN2HSP90AB1TDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684633-A | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-113195441-B | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20220380325-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-12-01 | — | — | US | disclosed |
| EP-3487853-B1 | BICYCLIC PROLINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| EP-3487853-B1 | BICYCLIC PROLINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| CN-109476640-B | Bicyclic proline compounds | 豪夫迈·罗氏有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-113195441-A | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | ESSA PHARMA, INC. (CA) | 2021-07-13 | — | — | US | disclosed |
| US-6893815-B1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030003505-A1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-20020009748-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-1999000669-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| EP-0458109-B1 | Side chain chlorination of alkylated pyridine or pyrimidine derivatives | BAYER AG (DE) | 1994-07-13 | — | — | EP | disclosed |
| US-5198549-A | SIDE-CHAIN CHLORINATION OF ALKYLATED NITROGEN HETEROAROMATICS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-03-30 | — | — | US | disclosed |
| EP-0458109-A1 | Side chain chlorination of alkylated pyridine or pyrimidine derivatives | BAYER AG (DE) | 1991-11-27 | — | — | EP | disclosed |
| EP-0114045-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS PESTICIDES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-09-03 | — | — | EP | disclosed |
| US-4584295-A | Pyrimidylmethyl thiophosphorus esters useful for the control of insects, mites and nematodes | HOFFMANN-LA ROCHE INC. (US) | 1986-04-22 | — | — | US | disclosed |
| EP-0114045-A1 | Pyrimidine derivatives and their use as pesticides | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020009748-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | PNP, ATIC, DPYD | SMN1; SMN2 894/4885HSP90AB1 4497/4885TDP1 252/4885 |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | AR, NR5A1, CYP17A1 | SMN1; SMN2 4842/4885HSP90AB1 892/4885TDP1 3384/4885 |
| US-20030003505-A1 | Nucleobase heterocyclic combinatorialization | PNP, ATIC, DPYD | SMN1; SMN2 894/4885HSP90AB1 4497/4885TDP1 252/4885 |
| US-20220380325-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | SMN1; SMN2 4842/4885HSP90AB1 892/4885TDP1 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.